Nuveen Asset Management LLC Has $1.56 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT)

Nuveen Asset Management LLC lowered its position in Altimmune, Inc. (NASDAQ:ALT) by 7.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 216,926 shares of the company’s stock after selling 17,504 shares during the period. Nuveen Asset Management LLC owned 0.31% of Altimmune worth $1,564,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ALT. SBI Securities Co. Ltd. bought a new position in shares of Altimmune in the fourth quarter valued at approximately $45,000. Virtus ETF Advisers LLC bought a new stake in Altimmune during the fourth quarter worth $60,000. Cullen Frost Bankers Inc. bought a new stake in Altimmune during the fourth quarter worth $72,000. KLP Kapitalforvaltning AS bought a new stake in Altimmune during the fourth quarter worth $81,000. Finally, Raymond James Financial Inc. bought a new stake in Altimmune during the fourth quarter worth $88,000. Institutional investors own 78.05% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Gregory L. Weaver bought 10,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was bought at an average price of $5.20 per share, with a total value of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on ALT shares. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Thursday, April 3rd. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Altimmune has an average rating of “Moderate Buy” and an average price target of $20.20.

Altimmune Stock Up 2.3%

Altimmune stock opened at $5.42 on Wednesday. Altimmune, Inc. has a 52 week low of $3.55 and a 52 week high of $11.16. The business has a 50-day simple moving average of $5.07 and a 200 day simple moving average of $6.39. The stock has a market cap of $439.60 million, a price-to-earnings ratio of -3.50 and a beta of 1.13.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. On average, research analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.